Healthcare Services

Cardiometabolic diseases market to reach $143.72B by 2030 at 4.6% CAGR

April 20, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

From Its 2026 Market Size, What Value Is The Cardiometabolic Diseases Market Projected To Reach By 2030?

The market for cardiometabolic diseases has experienced consistent growth in recent years. This sector is anticipated to expand from $115.27 billion in 2025 to $120.13 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 4.2%. Historically, this expansion has been driven by the increasing prevalence of obesity and diabetes, a rise in the incidence of hypertension and heart failure, the spread of urban sedentary lifestyles, growing awareness of cardiometabolic risks, and the presence of established therapeutic classes.

The cardiometabolic diseases market size is anticipated to demonstrate steady expansion in the coming years, with projections indicating a rise to $143.73 billion by 2030, growing at a compound annual growth rate (CAGR) of 4.6%. This growth during the forecast period is fueled by an escalating demand for personalized medicine, the increasing adoption of digital health tools, the broadening of early screening programs, a heightened focus on lifestyle-based interventions, and the ongoing development of novel cardiometabolic drugs. Prominent trends expected over this period encompass an increased emphasis on integrated disease management strategies, the rising use of combination drug therapies, the growing application of personalized treatment approaches, the expansion of preventive cardiometabolic care models, and a stronger focus on long-term disease monitoring.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/report/cardiometabolic-diseases-global-market-report

Which Key Drivers Are Affecting The Cardiometabolic Diseases Market Development?

The growing incidence of obesity is anticipated to fuel the expansion of the cardiometabolic disease market. Obesity is a multifaceted condition marked by an accumulation of excessive body fat, resulting in elevated body weight and various health issues. The frequency of obesity is on the rise as individuals increasingly adopt inactive lifestyles and consume high-calorie foods, factors that contribute to cardiovascular risk elements like type 2 diabetes, high blood pressure, abnormal lipid levels, and sleep disturbances. Managing cardiometabolic diseases involves tackling these risks through enhancing metabolic well-being and mitigating the complications linked with obesity. A notable example is found in May 2025, when the Office for Health Improvement and Disparities (OHID), a UK-government-agency, reported that approximately 64.5% of adults (18+) in England were estimated to be either overweight or obese during 2023–2024. This figure represents a slight increase from 64.0% recorded in the preceding period (2022–2023). Consequently, the elevated rate of obesity is stimulating the expansion of the cardiometabolic diseases market.

How Is The Cardiometabolic Diseases Market Organized By Segment Classification?

The cardiometabolic diseases market covered in this report is segmented –

1) By Type: Chronic Or Congestive Heart Failure, Hypertension, Type 2 Diabetes, Obesity

2) By Treatment: ACE inhibitors, Diuretics, Glucophage

3) By Dosage: Tablet, Injection

4) By End-Users: Clinic, Hospital, Other End-Users

Subsegments:

1) By Chronic Or Congestive Heart Failure: Systolic Heart Failure, Diastolic Heart Failure

2) By Hypertension: Primary Hypertension, Secondary Hypertension

3) By Type 2 Diabetes: Insulin Resistance, Impaired Glucose Tolerance

4) By Obesity: Class I Obesity (BMI 30-34.9), Class II Obesity (BMI 35-39.9), Class III Obesity (BMI 40 And above)

What Trends Are Transforming The Cardiometabolic Diseases Market?

Leading companies in the cardiometabolic diseases market are actively implementing advanced technologies, such as the introduction of cardiac disease detection platforms, to improve the early diagnosis and ongoing monitoring of cardiovascular conditions. A cardiac disease detection platform launch refers to the deployment of a specialized system designed to identify, monitor, and assess cardiovascular conditions using sophisticated diagnostic technologies, sensors, and data analytics, with the aim of enabling earlier detection, enhancing patient outcomes, and supporting clinical decision-making. For instance, in February 2023, Eko Health Inc., a US-based innovator of digital health technologies for detecting heart and lung diseases, introduced its Sensora cardiac disease detection platform. This system incorporates artificial intelligence (AI) that reliably identifies structural murmurs, which are indicators of valvular heart disease (VHD), along with care pathway analytics software that provides metrics and subsequent insights into a patient’s progression through the healthcare system. This particular digital stethoscope is utilized to capture and analyze electrical impulses and heartbeats.

Who Are The Industry Participants Involved In The Cardiometabolic Diseases Market?

Major companies operating in the cardiometabolic diseases market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche AG, Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi SA, Kowa Company Ltd., Abbott Laboratories, Takeda Pharmaceutical Company, Eli Lilly and Company, Novo Nordisk A/S, Siemens Healthineers, Boehringer Ingelheim International GmbH, Becton Dickinson and Company, Stryker Corporation, AstraZeneca Plc, Viatris Inc., Boston Scientific, Astellas Pharma Inc., Terumo Corporation, Edwards Lifesciences, Alnylam Pharmaceuticals Inc., Arrowhead Pharmaceuticals Inc., Cardax Inc.

Get The Full Cardiometabolic Diseases Market Report:

https://www.thebusinessresearchcompany.com/report/cardiometabolic-diseases-global-market-report

Where Is The Cardiometabolic Diseases Market Most Concentrated Geographically?

North America was the largest region in the cardiometabolic diseases market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cardiometabolic diseases market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Cardiometabolic Diseases Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/cardiometabolic-diseases-global-market-report

Browse Through More Reports Similar to the Global Cardiometabolic Diseases Market 2026, By The Business Research Company

Cardiovascular Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/cardiovascular-drugs-global-market-report

Hypertrophic Cardiomyopathy Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/hypertrophic-cardiomyopathy-treatment-global-market-report

Heart Attack Diagnostic Market Report 2026

https://www.thebusinessresearchcompany.com/report/heart-attack-diagnostic-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795